CN111194356B - 用于检测浆细胞恶病质的方法 - Google Patents

用于检测浆细胞恶病质的方法 Download PDF

Info

Publication number
CN111194356B
CN111194356B CN201880061441.9A CN201880061441A CN111194356B CN 111194356 B CN111194356 B CN 111194356B CN 201880061441 A CN201880061441 A CN 201880061441A CN 111194356 B CN111194356 B CN 111194356B
Authority
CN
China
Prior art keywords
splice variant
subject
expression level
comprises exons
splice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880061441.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN111194356A (zh
Inventor
I.M.莫林
M.基德
I.德罗斯多夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Liquid Biopsy Research LLC
Original Assignee
Liquid Biopsy Research LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liquid Biopsy Research LLC filed Critical Liquid Biopsy Research LLC
Publication of CN111194356A publication Critical patent/CN111194356A/zh
Application granted granted Critical
Publication of CN111194356B publication Critical patent/CN111194356B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6818—Sequencing of polypeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Data Mining & Analysis (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201880061441.9A 2017-07-21 2018-07-18 用于检测浆细胞恶病质的方法 Active CN111194356B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762535419P 2017-07-21 2017-07-21
US62/535419 2017-07-21
PCT/US2018/042712 WO2019018540A1 (en) 2017-07-21 2018-07-18 METHODS FOR DETECTION OF PLASMOCYTE DYSGLOBULINEMIA

Publications (2)

Publication Number Publication Date
CN111194356A CN111194356A (zh) 2020-05-22
CN111194356B true CN111194356B (zh) 2024-04-23

Family

ID=63244986

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880061441.9A Active CN111194356B (zh) 2017-07-21 2018-07-18 用于检测浆细胞恶病质的方法

Country Status (14)

Country Link
US (2) US20190025311A1 (enExample)
EP (1) EP3655553B1 (enExample)
JP (1) JP7223741B2 (enExample)
KR (1) KR102785072B1 (enExample)
CN (1) CN111194356B (enExample)
AU (1) AU2018304242B2 (enExample)
BR (1) BR112020000791A2 (enExample)
CA (1) CA3067730A1 (enExample)
DK (1) DK3655553T3 (enExample)
ES (1) ES2916450T3 (enExample)
IL (1) IL271465B2 (enExample)
MX (1) MX2020000785A (enExample)
PL (1) PL3655553T3 (enExample)
WO (1) WO2019018540A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2916450T3 (es) 2017-07-21 2022-07-01 Liquid Biopsy Res Llc Método para la detección de discrasia de células plasmáticas
US20210108259A1 (en) 2019-10-10 2021-04-15 Liquid Biopsy Research LLC Compositions, methods and kits for biological sample and rna stabilization
CN111349705A (zh) * 2020-03-18 2020-06-30 昆明医科大学 circASXL1作为肺癌诊断标志物及其运用
US20230203587A1 (en) * 2020-05-29 2023-06-29 Exosome Diagnostics, Inc. Use of microvesicle signature for the diagnosis and treatment of kidney transplant rejection

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004313167A (ja) * 2003-02-24 2004-11-11 Joji Inasawa 薬剤耐性マーカーおよびその利用
JP2005512557A (ja) * 2001-11-07 2005-05-12 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ アーカンソー 遺伝子発現プロファイリングに基づく多発性骨髄腫の診断、予後、および治療標的候補の同定
JP2008544223A (ja) * 2005-06-08 2008-12-04 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 癌治療を受けている患者の同定、判定および処置のための方法
WO2010078531A2 (en) * 2009-01-02 2010-07-08 The Board Of Trustees Of The University Of Arkansas Uses of bortezomib in predicting survival in multiple myeloma patients
WO2011152884A2 (en) * 2010-06-04 2011-12-08 Board Of Trustees Of The University Of Arkansas 14 gene signature distinguishes between multiple myeloma subtypes
WO2013155048A1 (en) * 2012-04-10 2013-10-17 University Of Utah Research Foundation Compositions and methods for diagnosing and classifying multiple myeloma

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3002661C (en) * 2004-05-21 2022-03-15 The Board Of Trustees Of The University Of Arkansas Use of gene expression profiling to predict survival in cancer patient
ES2916450T3 (es) 2017-07-21 2022-07-01 Liquid Biopsy Res Llc Método para la detección de discrasia de células plasmáticas

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005512557A (ja) * 2001-11-07 2005-05-12 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ アーカンソー 遺伝子発現プロファイリングに基づく多発性骨髄腫の診断、予後、および治療標的候補の同定
JP2004313167A (ja) * 2003-02-24 2004-11-11 Joji Inasawa 薬剤耐性マーカーおよびその利用
JP2008544223A (ja) * 2005-06-08 2008-12-04 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 癌治療を受けている患者の同定、判定および処置のための方法
WO2010078531A2 (en) * 2009-01-02 2010-07-08 The Board Of Trustees Of The University Of Arkansas Uses of bortezomib in predicting survival in multiple myeloma patients
CN102361991A (zh) * 2009-01-02 2012-02-22 阿肯色大学托管委员会 硼替佐米在预测多发性骨髓瘤患者生存率中的应用
WO2011152884A2 (en) * 2010-06-04 2011-12-08 Board Of Trustees Of The University Of Arkansas 14 gene signature distinguishes between multiple myeloma subtypes
WO2013155048A1 (en) * 2012-04-10 2013-10-17 University Of Utah Research Foundation Compositions and methods for diagnosing and classifying multiple myeloma

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival;C Botta 等;《Blood Cancer Journal》;20161216;第6卷;第1-8页 *
Gene Expression Profiles in Myeloma: Ready for the Real World?;Raphael Szalat 等;《Clin Cancer Res》;20161115;第22卷(第22期);第5434-5442页 *
Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis;Fenghuang Zhan 等;《Blood》;20070215;第109卷(第4期);第1692-1700页 *
骨标志物与多发性骨髓瘤疾病进展的相关性研究;刘彦 等;《中国实验血液学杂志》;20161231;第24卷(第5期);第1433-1436页 *

Also Published As

Publication number Publication date
KR20200029528A (ko) 2020-03-18
DK3655553T3 (da) 2022-06-20
WO2019018540A1 (en) 2019-01-24
US12366575B2 (en) 2025-07-22
US20190025311A1 (en) 2019-01-24
US20230022417A1 (en) 2023-01-26
IL271465B1 (en) 2023-04-01
PL3655553T3 (pl) 2022-09-26
BR112020000791A2 (pt) 2020-07-21
KR102785072B1 (ko) 2025-03-20
CA3067730A1 (en) 2019-01-24
EP3655553A1 (en) 2020-05-27
AU2018304242B2 (en) 2023-04-27
IL271465A (en) 2020-01-30
JP2020528274A (ja) 2020-09-24
ES2916450T3 (es) 2022-07-01
JP7223741B2 (ja) 2023-02-16
AU2018304242A1 (en) 2020-01-16
CN111194356A (zh) 2020-05-22
EP3655553B1 (en) 2022-03-23
MX2020000785A (es) 2020-11-06
IL271465B2 (en) 2023-08-01

Similar Documents

Publication Publication Date Title
Guarini et al. ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression
CN106834462B (zh) 一组胃癌基因的应用
JP2015512630A (ja) 急性骨髄性白血病の診断、予後、及び治療用の方法及び組成物
US10745761B2 (en) Method and systems for lung cancer diagnosis
CN111194356B (zh) 用于检测浆细胞恶病质的方法
US20120141603A1 (en) Methods and compositions for lung cancer prognosis
KR20180009762A (ko) 폐암을 진단하거나 검출하기 위한 방법 및 조성물
JP2011509689A (ja) Ｉｉ及びｉｉｉ期結腸癌の分子病期分類並びに予後診断
Porpaczy et al. Gene expression signature of chronic lymphocytic leukaemia with Trisomy 12
JP2019537436A (ja) 進行性胃癌患者の手術後の予後または抗癌剤適合性予測システム
US20250137066A1 (en) Compostions and methods for diagnosing lung cancers using gene expression profiles
WO2014173905A2 (en) Methods and kits for prognosis of stage i nsclc by determining the methylation pattern of cpg dinucleotides
JP2022023238A (ja) 多発性骨髄腫のためのｇｅｐ５モデル
KR102195591B1 (ko) Glut3의 다형성을 이용한 비소세포폐암의 예후 진단 방법
KR102195593B1 (ko) Ddc의 다형성을 이용한 소세포폐암의 예후 진단 방법
KR101774747B1 (ko) Ｐｃａｆ의 다형성을 이용한 비소세포폐암의 예후 진단 방법
Yang et al. Mutations of METTL3 predict response to neoadjuvant chemotherapy in muscle-invasive bladder cancer
Meena et al. Molecular evaluation of gene mutation profiles and copy number variations in pediatric acute myeloid leukemia
CN111315897B (zh) 用于黑素瘤检测的方法
KR102384992B1 (ko) 대장암 환자의 연령 특이적 바이오마커 및 이의 용도
Cao et al. Clinical evaluation of integrated panel testing by next-generation sequencing for somatic mutations in neuroblastomas with MYCN unamplification
JP2014501496A (ja) 消化管間質腫瘍における臨床転帰のシグネチャーおよび消化管間質腫瘍の治療の方法
HK40030202B (en) Methods for detection of plasma cell dyscrasia
HK40030202A (en) Methods for detection of plasma cell dyscrasia
KR101895677B1 (ko) Dtx1의 다형성을 이용한 비소세포폐암의 예후 진단 방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant